학술논문
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti–PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort
Document Type
Article
Author
Source
In: Lung Cancer . (Lung Cancer, May 2021, 155:151-155)
Subject
Language
English
ISSN
18728332
01695002
01695002